Paratek Pharmaceuticals Inc  

(Public, NASDAQ:PRTK)   Watch this stock  
Find more results for NASDAQ:TSPT
15.10
-0.25 (-1.63%)
Feb 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.68 - 15.40
52 week 9.80 - 18.92
Open 15.35
Vol / Avg. 244,980.00/153,949.00
Mkt cap 336.11M
P/E     -
Div/yield     -
EPS -5.17
Shares 22.63M
Beta 1.29
Inst. own 89%
Feb 21, 2017
Q4 2016 Paratek Pharmaceuticals Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -65.13% -55.38%
Return on average equity -98.76% -72.14%
Employees 41 -
CDP Score - -

Address

75 Park Plz Ste 4
BOSTON, MA 02116-3934
United States - Map
+1-617-8076600 (Phone)
+1-617-2750039 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Paratek Pharmaceuticals, Inc. (Paratek), formerly Transcept Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek's antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI). The Company's sarecycline is a Phase III antibacterial product candidate and was previously known as WC3035. Sarecycline is designed for use in the treatment of acne and rosacea. The Company's other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class.

Officers and directors

Michael F. Bigham CPA Chairman of the Board, Chief Executive Officer
Age: 57
Bio & Compensation  - Reuters
Evan Loh M.D. President, Chief Operating Officer, Chief Medical Officer, Director
Age: 57
Bio & Compensation  - Reuters
Douglas W Pagan Chief Financial Officer
Age: 44
Bio & Compensation  - Reuters
William M. Haskel Senior Vice President, General Counsel, Corporate Secretary
Age: 53
Bio & Compensation  - Reuters
Regina D. Paglia Senior Vice President - Human Resources
Bio & Compensation  - Reuters
Jeanne Jew Senior Vice President - Business Development
Bio & Compensation  - Reuters
Evan Tzanis Senior Vice President - Clinical Development and Clinical Operations
Bio & Compensation  - Reuters
Rajesh Padmanabhan Vice President - Information Technology
Bio & Compensation  - Reuters
Stephen Villano M.D. Vice President - Clinical and Medical Affairs
Bio & Compensation  - Reuters
Adam Woodrow Vice President and Chief Commercial Officer
Age: 48
Bio & Compensation  - Reuters